We are very excited to announce that the proposal to grow and expand the MAPcore Translational Research Core Platform received funding from the Faculty of Medicine Strategic Investment Fund (SIF).
MAPcore is a key technology platform for the Academy of Translational Medicine (ATM) and the UBC translational research community. The SIF funding will be utilized to expand and accelerate the transition of MAPcore from an investigator-driven lab to a fully-functional core facility available to the research community in BC. This will involve hiring research personnel to offer core services to support the most advanced molecular pathology research and develop MAPcore as a functional business unit. W
MAPcore is led by Drs. David Huntsman, David Schaeffer and Torsten Nielsen with organizational support from ATM leadership.
“We look forward to working with the ATM to empower UBC researcher through access to state-of-the-art pathology and molecular pathology technology and expertise” said Huntsman. “Through the support from the SIF program and CFI we have retooled MAPcore to enable it to work with diagnostic discoveries made from today’s lead research platforms including single cell genomics and proteomics.”
The Faculty of Medicine received 22 proposals for the Summer 2022 Strategic Investment Fund (SIF) call. Following detailed review, the Dean selected eight proposals for funding based on the advisory group’s recommendations, for a total allocation of $1.01M.
We congratulate all the successful applicants!
Read the full list of funded proposals and more about SIF here.